Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma

Scott W. Fosko, Melinda B. Chu, Adam R. Mattox, John M. Richart, Nicole M. Burkemper, Jordan B. Slutsky

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report an 83 year-old patient with a 13 × 7.5 cm2 basal cell carcinoma (BCC) successfully treated with the combination of vismodegib and minimal surgery. On Day 109, a 0.9 cm papule suspicious for residual BCC was seen centrally within a large pink atrophic plaque. This lesion was excised; pathology confirmed BCC with negative surgical margins. Simultaneously, suspecting noncontiguous histologic response, we performed 21 biopsies at the periphery of the pretreatment tumor location. Seventeen (17/21, 81%) revealed lichenoid dermatitis. No tumor was seen on any. We believe the lichenoid dermatitis observed is a novel finding for two reasons. First, it may be considered a marker of a positive intratreatment response. This may help guide clinicians on the optimal treatment duration of vismodegib to maximize efficacy and mitigate side effects. Second, we think it suggests an additional mechanism of vismodegib action, possibly via local immune effects. Further investigations are warranted.

Original languageEnglish (US)
Pages (from-to)359-362
Number of pages4
JournalDermatologic Therapy
Volume28
Issue number6
DOIs
StatePublished - Nov 1 2015

Fingerprint

HhAntag691
Giant Cell Carcinoma
Basal Cell Carcinoma
Biomarkers
Dermatitis
Neoplasms
Therapeutics
Pathology
Biopsy

Keywords

  • basal cell carcinoma
  • lichenoid dermatitis
  • neoadjuvant
  • treatment response
  • vismodegib

Cite this

Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma. / Fosko, Scott W.; Chu, Melinda B.; Mattox, Adam R.; Richart, John M.; Burkemper, Nicole M.; Slutsky, Jordan B.

In: Dermatologic Therapy, Vol. 28, No. 6, 01.11.2015, p. 359-362.

Research output: Contribution to journalArticle

Fosko, Scott W. ; Chu, Melinda B. ; Mattox, Adam R. ; Richart, John M. ; Burkemper, Nicole M. ; Slutsky, Jordan B. / Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma. In: Dermatologic Therapy. 2015 ; Vol. 28, No. 6. pp. 359-362.
@article{85760d248d604d89a187955031a74312,
title = "Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma",
abstract = "We report an 83 year-old patient with a 13 × 7.5 cm2 basal cell carcinoma (BCC) successfully treated with the combination of vismodegib and minimal surgery. On Day 109, a 0.9 cm papule suspicious for residual BCC was seen centrally within a large pink atrophic plaque. This lesion was excised; pathology confirmed BCC with negative surgical margins. Simultaneously, suspecting noncontiguous histologic response, we performed 21 biopsies at the periphery of the pretreatment tumor location. Seventeen (17/21, 81{\%}) revealed lichenoid dermatitis. No tumor was seen on any. We believe the lichenoid dermatitis observed is a novel finding for two reasons. First, it may be considered a marker of a positive intratreatment response. This may help guide clinicians on the optimal treatment duration of vismodegib to maximize efficacy and mitigate side effects. Second, we think it suggests an additional mechanism of vismodegib action, possibly via local immune effects. Further investigations are warranted.",
keywords = "basal cell carcinoma, lichenoid dermatitis, neoadjuvant, treatment response, vismodegib",
author = "Fosko, {Scott W.} and Chu, {Melinda B.} and Mattox, {Adam R.} and Richart, {John M.} and Burkemper, {Nicole M.} and Slutsky, {Jordan B.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/dth.12260",
language = "English (US)",
volume = "28",
pages = "359--362",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma

AU - Fosko, Scott W.

AU - Chu, Melinda B.

AU - Mattox, Adam R.

AU - Richart, John M.

AU - Burkemper, Nicole M.

AU - Slutsky, Jordan B.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - We report an 83 year-old patient with a 13 × 7.5 cm2 basal cell carcinoma (BCC) successfully treated with the combination of vismodegib and minimal surgery. On Day 109, a 0.9 cm papule suspicious for residual BCC was seen centrally within a large pink atrophic plaque. This lesion was excised; pathology confirmed BCC with negative surgical margins. Simultaneously, suspecting noncontiguous histologic response, we performed 21 biopsies at the periphery of the pretreatment tumor location. Seventeen (17/21, 81%) revealed lichenoid dermatitis. No tumor was seen on any. We believe the lichenoid dermatitis observed is a novel finding for two reasons. First, it may be considered a marker of a positive intratreatment response. This may help guide clinicians on the optimal treatment duration of vismodegib to maximize efficacy and mitigate side effects. Second, we think it suggests an additional mechanism of vismodegib action, possibly via local immune effects. Further investigations are warranted.

AB - We report an 83 year-old patient with a 13 × 7.5 cm2 basal cell carcinoma (BCC) successfully treated with the combination of vismodegib and minimal surgery. On Day 109, a 0.9 cm papule suspicious for residual BCC was seen centrally within a large pink atrophic plaque. This lesion was excised; pathology confirmed BCC with negative surgical margins. Simultaneously, suspecting noncontiguous histologic response, we performed 21 biopsies at the periphery of the pretreatment tumor location. Seventeen (17/21, 81%) revealed lichenoid dermatitis. No tumor was seen on any. We believe the lichenoid dermatitis observed is a novel finding for two reasons. First, it may be considered a marker of a positive intratreatment response. This may help guide clinicians on the optimal treatment duration of vismodegib to maximize efficacy and mitigate side effects. Second, we think it suggests an additional mechanism of vismodegib action, possibly via local immune effects. Further investigations are warranted.

KW - basal cell carcinoma

KW - lichenoid dermatitis

KW - neoadjuvant

KW - treatment response

KW - vismodegib

UR - http://www.scopus.com/inward/record.url?scp=84955208462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955208462&partnerID=8YFLogxK

U2 - 10.1111/dth.12260

DO - 10.1111/dth.12260

M3 - Article

VL - 28

SP - 359

EP - 362

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 6

ER -